Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 19;36(23):3263–3273. doi: 10.1038/onc.2016.471

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Inhibition of RALB activity with dinaciclib potently suppresses leukemic colony formation in vitro and prevents NRI AML relapse in vivo. (a) Leukemia colony-forming cell (L-CFC) frequencies for splenocytes harvested from leukemic mice treated for 16 h with dinaciclib, ABT-737 or ABT-199 relative to DMSO vehicle controls (n=3 independent experiments, error bars=1 s.d., *P<0.05) (b) White blood cell counts (WBCs) of leukemic NRG mice transplanted with a 1:1 mix of NRD and NRI1 AML cells treated with control vehicle, continuous doxycycline (Dox) to suppress NRAS(V12) expression or 5 days per week of 15 mg/kg per day dinaciclib (each symbol represents an individual mouse, bars=mean±1 s.d., *P<0.05 between Dox- and dinaciclib-treated mice).